Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of polypeptide, immunogenic conjugate and influenza vaccine

A technology of immunogenicity and influenza vaccine, applied in the biological field, can solve the problems of small molecular weight and poor immunogenicity, and achieve the effect of increasing molecular weight, preventing death, and improving immunogenicity

Active Publication Date: 2021-06-01
华兰生物疫苗股份有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, synthetic peptide vaccines generally have a small molecular weight and only target a single antigenic site, resulting in poor immunogenicity, better immunity to sequence-dependent antigenic sites, and poorer conformation-dependent sites

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of polypeptide, immunogenic conjugate and influenza vaccine
  • A kind of polypeptide, immunogenic conjugate and influenza vaccine
  • A kind of polypeptide, immunogenic conjugate and influenza vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Design and synthesis of polypeptide M2A6:

[0076] 1. Design of polypeptide M2A6

[0077] Due to the high conservation of influenza virus M2e protein, it has become the research target of general influenza vaccine. The present invention designs a polypeptide M2A6 by comparing the sequences of about 13,000 influenza strains from NCBI, and its amino acid sequence is shown in SEQ ID NO.1, and it is named as polypeptide M2A6.

[0078] 2. Synthesis of polypeptide M2A6

[0079] The present invention adopts polypeptide solid-phase synthesis method to synthesize polypeptide M2A6. Based on Fmoc chemical synthesis, the carboxyl group of the C-terminal amino acid of the target polypeptide to be synthesized is first connected with an insoluble polymer resin in the form of a covalent bond, and then the amino acid is As the starting point of peptide synthesis, the amino group of the amino acid reacts with the activated carboxyl group of other amino acids to form a peptide bond. Thi...

Embodiment 2

[0095] Preparation of immunogen CRM197-M2A6 and its immune effect

[0096] 1. Preparation of immunogen CRM197-M2A6

[0097] 1. Solution preparation:

[0098] (1) Preparation of carrier protein solution: with CRM197 protein (shown in the amino acid sequence of CRM197 protein SEQ ID NO.2) as carrier protein, PBS buffer (20mM phosphate, 150mM sodium chloride, pH7.4) as solvent, Prepare the carrier protein solution to obtain a carrier protein solution with a concentration of 5 g / mL.

[0099] (2) Preparation of SMCC solution: According to 80× excess calculation, 6.69 mg of heterobifunctional cross-linking agent SMCC was weighed and dissolved in 334 μL of DMF solution to obtain a SMCC solution with a concentration of 20 mg / mL;

[0100] (3) Preparation of target peptide solution: Calculated by 10×, weigh 6.81 mg of the polypeptide M2A6 prepared in Example 1 above and dissolve it in 2.27 mL of PBS buffer to obtain a target peptide solution with a concentration of 3 mg / mL.

[0101] ...

Embodiment 3

[0113] Preparation of CRM197-M2A6 conjugate vaccine and its immune effect

[0114] 1. Preparation of CRM197-M2A6 conjugate vaccine

[0115] Dilute the immunogen CRM197-M2A6 prepared in Example 2 with PBS buffer (20 mM phosphate, 150 mM sodium chloride, pH7.4) to a concentration of 250 μg / mL, and then slowly add aluminum hydroxide adjuvant , ensure that the final concentration of aluminum hydroxide adjuvant is 2.5 mg / mL, and shake the sample slowly during the dropping process. After adding aluminum hydroxide, seal the sample well, place it at 2-8°C and slowly shake it for 15-18 hours after adsorption, 15-18 hours (16 hours is the best, according to the adsorption time, 16 hours has the best immune effect). Afterwards, it was diluted to a final antigen concentration of 100 μg / mL to obtain a CRM197-M2A6 conjugate vaccine.

[0116] Second, the detection of antibody titer

[0117] Inject the CRM197-M2A6 conjugate vaccine prepared in Step 1 by intraperitoneal injection. The immu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
degree of substitutionaaaaaaaaaa
Login to View More

Abstract

The invention discloses a polypeptide, an immunogenic conjugate and an influenza vaccine, and relates to the field of biotechnology. The polypeptide is any one of the following a), b) or c): a) the amino acid sequence of the polypeptide shown in SEQ ID NO.1; b) the amino acid sequence of the polypeptide shown in SEQ ID NO.1 N c) the amino acid sequence shown in SEQ ID NO.1 through the substitution and / or deletion and / or addition of one or several amino acid residues and has the same function peptide. It can be used to prevent or treat influenza virus, and can be used as an active ingredient to prepare medicines for preventing or treating influenza virus. The immunogenic conjugate disclosed in the present invention can improve immunogenicity and its immune effect on antigens at conformation-dependent sites.

Description

technical field [0001] The invention relates to the technical field of biotechnology, in particular to a polypeptide, an immunogenic conjugate and an influenza vaccine. Background technique [0002] Influenza A virus is a common influenza virus. Influenza A virus is the most likely to mutate. The subtype of influenza A virus is called "bird flu". Bird flu (Bird Flu) is caused by bird flu virus. Acute infectious disease, virus gene mutation can infect human beings, the main symptoms after infection are high fever, cough, runny nose, myalgia, etc. Most of them are accompanied by severe pneumonia. In severe cases, heart, kidney and other organ failure lead to death , the fatality rate is high. Influenza A is highly pathogenic to humans and has caused worldwide pandemics many times. Among the influenza A viruses, the subtypes of avian influenza viruses that can directly infect humans have been found so far: A H1N1, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N8. Among the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/11C07K19/00A61K39/385A61K39/145A61P31/16
CPCA61K39/12A61K39/385A61K2039/6037C07K14/005C07K2319/55C12N2760/16122C12N2760/16134
Inventor 梁雪爽刘晓刚安文琪张静静郝一楠王满满师方园
Owner 华兰生物疫苗股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com